DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1960)

Type 2 Diabetes | Access and Reimbursement | US | 2016

Type 2 Diabetes | Access and Reimbursement | US | 2016

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The type 2 diabetes market has become increasingly crowded, with therapies competing over preferential formulary placement as well as patient share. Using primary research from U.S. endocrinologists, primary care physicians, and managed care organization medical/pharmacy directors, this content examines market access factors in the United States. The interaction between payers and physicians, including how reimbursement decisions impact prescribing and uptake of therapies at the brand level, will help unravel treatment drivers in the second line following metformin monotherapy.

Already a Client? Log in to access this report.

  • Pub Date: July 2016

Purchase Report

Recent reports:
You may also be interested in: